Welcome to our dedicated page for Radnostix news (Ticker: INIS), a resource for investors and traders seeking the latest updates and insights on Radnostix stock.
International Isotopes Inc. (INIS), now known corporately as Radnostix, Inc., generates a steady flow of news related to its radioisotope, theranostics, and medical device activities. Headquartered in Idaho Falls, Idaho and incorporated in Texas, the company reports across several segments, including Theranostics Products, Calibration & Reference Products (formerly Nuclear Medicine Standards), Cobalt Products, Medical Devices, and a Fluorine Products segment associated with a proposed de-conversion facility.
News updates frequently cover quarterly and annual financial results, where the company discusses revenue trends, segment performance, gross profit, and the use of non-GAAP measures such as EBITDA and Adjusted EBITDA. These releases often highlight demand for generic sodium iodide I-131 radiopharmaceutical drug product, I-131 theranostic APIs, calibration and reference standards, and Cobalt-60 sealed source products, as well as the impact of global isotope supply conditions, such as shortages of Cobalt-57 and Gadolinium-153.
Investors and industry observers can also find corporate development news, including the legal name change to Radnostix, Inc., governance and bylaw changes, executive employment agreements, and board appointments. Operational news has included expansion of the company’s footprint in Idaho Falls through land acquisition and a new facility lease, which the company states is intended to support capacity growth across its segments.
Product and partnership announcements feature prominently as well. Examples include the creation of the PhanQual joint venture with Phantech Medical for pre-clinical calibration sources, the manufacturing joint venture with Alpha Nuclides to bring INIS and RadQual products into China via Radnostix China, and updates on the RadVent medical device lineup and EasyFill Automated Iodine Capsule System. For users tracking INIS, this news stream provides insight into segment dynamics, supply chain developments, facility expansion, and the company’s evolving theranostics and healthcare focus.
International Isotopes Inc. (INIS) reported financial results for Q2 and H1 2024. Key highlights include:
- Theranostics Sales increased 25% in Q2 and 16% in H1 2024
- Gross Profit improved to 64%, a 7% increase, for H1 2024
- Net Cash Provided from Operations of $288,597 for H1 2024
- Q2 revenue was $3,169,233, up 2% year-over-year
- H1 revenue was $6,073,691, down 2% year-over-year
- Q2 net loss narrowed to $233,445 from $263,302 in Q2 2023
- H1 net loss narrowed to $387,496 from $411,356 in H1 2023
The company saw growth in Theranostics and Cobalt Products, offset by declines in Nuclear Medicine Standards due to a global Cobalt-57 shortage. INIS expects continued growth in Theranostics and anticipates catching up on backlogged Nuclear Medicine orders in H2 2024.
International Isotopes (OTCQB: INIS) announced its fiscal Q1 2024 results, revealing a 6% decline in revenue to $2.90M from $3.09M in Q1 2023 due to global Cobalt-57 isotope shortages. Nonetheless, the Theranostics Products segment experienced an 8% revenue growth, and the Cobalt Products segment saw a 48% increase. Gross profit rose by 5% to $1.87M, while the net loss widened slightly to $154K from $148K in Q1 2023. Operating income also decreased by 80%. Cash and cash equivalents decreased to $2.37M from $2.69M at the end of 2023. Despite isotope constraints, the company anticipates growth in the Nuclear Medicine segment by late Q3 2024 and plans to commercialize new Medical Devices later this year.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
International Isotopes Inc. reported a significant 16% increase in revenue for the fiscal year 2022, totaling